WINTON GROUP Ltd lifted its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 33.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,700 shares of the company’s stock after acquiring an additional 3,927 shares during the quarter. WINTON GROUP Ltd’s holdings in Revolution Medicines were worth $498,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently bought and sold shares of RVMD. Cormorant Asset Management LP increased its holdings in shares of Revolution Medicines by 1.2% in the 1st quarter. Cormorant Asset Management LP now owns 2,525,000 shares of the company’s stock worth $115,847,000 after acquiring an additional 29,934 shares during the period. Royal Bank of Canada raised its holdings in Revolution Medicines by 1,128.6% during the first quarter. Royal Bank of Canada now owns 6,094 shares of the company’s stock valued at $280,000 after buying an additional 5,598 shares in the last quarter. Fiduciary Trust Co. acquired a new stake in Revolution Medicines in the 1st quarter valued at approximately $454,000. Principal Financial Group Inc. raised its position in Revolution Medicines by 1.6% in the first quarter. Principal Financial Group Inc. now owns 23,761 shares of the company’s stock worth $1,090,000 after purchasing an additional 374 shares in the last quarter. Finally, Baker BROS. Advisors LP bought a new position in Revolution Medicines in the 1st quarter worth approximately $10,196,000. 95.49% of the stock is currently owned by institutional investors and hedge funds.
Several analysts have recently issued reports on the company. Zacks Investment Research lowered Revolution Medicines from a “hold” rating to a “sell” rating in a report on Tuesday, August 17th. The Goldman Sachs Group downgraded shares of Revolution Medicines from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $49.00 to $27.00 in a research note on Thursday, August 12th. Guggenheim decreased their target price on Revolution Medicines from $52.00 to $34.00 and set a “buy” rating for the company in a research report on Thursday, August 12th. SVB Leerink cut their target price on Revolution Medicines from $46.00 to $38.00 and set an “outperform” rating on the stock in a research note on Thursday, August 12th. Finally, HC Wainwright reduced their price target on Revolution Medicines from $55.00 to $31.00 and set a “buy” rating for the company in a research report on Tuesday, August 17th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Revolution Medicines presently has an average rating of “Hold” and a consensus price target of $34.80.
Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, August 11th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.04). The business had revenue of $8.70 million for the quarter, compared to analyst estimates of $10.81 million. Revolution Medicines had a negative return on equity of 23.94% and a negative net margin of 355.11%. Sell-side analysts anticipate that Revolution Medicines, Inc. will post -2.45 EPS for the current year.
Revolution Medicines Company Profile
Revolution Medicines, Inc, a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors.
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.